moatshark My

All holdings

IDEXX Laboratories

IDXX

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
6
In their latest 13F (Q3 2026)
See who
Value held
$893m
Combined value at quarter end
Last quarter
1 bought
3 sold or trimmed
Fund portfolios
5
Funds holding it
See which
Price at Q2 ’26 end
$526.44
-6.3% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+3.7%Q3 ’24
-18.2%Q4 ’24
+1.6%Q1 ’25
+27.7%Q2 ’25
+19.1%Q3 ’25
+5.9%Q4 ’25
-16.9%Q1 ’26
-6.3%Q2 ’26
Q3 ’24: +3.7%; Q4 ’24: -18.2%; Q1 ’25: +1.6%; Q2 ’25: +27.7%; Q3 ’25: +19.1%; Q4 ’25: +5.9%; Q1 ’26: -16.9%; Q2 ’26: -6.3%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

2Q4 ’23
2Q1 ’24
3Q2 ’24
3Q3 ’24
3Q4 ’24
4Q1 ’25
5Q2 ’25
6Q3 ’25
6Q4 ’25
6Q1 ’26
6Q2 ’26
0Q3 ’26
Q4 ’23: 2; Q1 ’24: 2; Q2 ’24: 3; Q3 ’24: 3; Q4 ’24: 3; Q1 ’25: 4; Q2 ’25: 5; Q3 ’25: 6; Q4 ’25: 6; Q1 ’26: 6; Q2 ’26: 6; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes IDEXX Laboratories.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding IDEXX Laboratories
Fundsmith3.9%$537m$537mTrimmed -30%46 qtrs
Polen Capital Management2.4%$280m$280mTrimmed -23%5 qtrs
Jensen Investment Management1.4%$55.6m$55.6mAdded +2861%9 qtrs
Weitz Investment Management1.3%$18.6m$18.6mUnchanged6 qtrs
Mairs & Power0.0%$1.1m$1.1mUnchanged51 qtrs
Harris Associates (Oakmark)0.0%$240k$240kTrimmed -5.6%4 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of IDEXX Laboratories
Bought or soldFiling
4 Sep 2026Kingsley Lawrence DDirector▼ Sold2,203$532.08$1.2mForm 4

About the company

Sector
Health care · In Vitro & In Vivo Diagnostic Substances
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
79m at 31 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$1.4bn2013
$1.6bn2015
$2.0bn2017
$2.4bn2019
$3.2bn2021
$3.7bn2023
$4.3bn2025
2013: $1.4bn; 2014: $1.5bn; 2015: $1.6bn; 2016: $1.8bn; 2017: $2.0bn; 2018: $2.2bn; 2019: $2.4bn; 2020: $2.7bn; 2021: $3.2bn; 2022: $3.4bn; 2023: $3.7bn; 2024: $3.9bn; 2025: $4.3bn
IDEXX Laboratories revenue and net income by year
YearRevenueNet income
2025$4.3bn$1.1bn
2024$3.9bn$888m
2023$3.7bn$845m
2022$3.4bn$679m
2021$3.2bn$745m
2020$2.7bn$582m
2019$2.4bn$428m
2018$2.2bn$377m
2017$2.0bn$263m
2016$1.8bn$222m
2015$1.6bn$192m
2014$1.5bn$182m
2013$1.4bn$188m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold IDEXX Laboratories, from their latest N-PORT filings.

Funds holding IDEXX Laboratories
Polen Global Growth FundPolen Capital Management2.1%$2.3m31 Jul 2026
Fundsmith Equity ETFFundsmith1.8%$141k30 Jun 2026
Weitz Large Cap Equity FundWeitz Investment Management1.7%$10.5m30 Jun 2026
Weitz Partners Value FundWeitz Investment Management1.6%$7.9m30 Jun 2026
Jensen Quality Growth FundJensen Investment Management1.5%$45.1m31 May 2026